Department of Woman's, Child's and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy,
Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Rome, Italy.
Chemotherapy. 2020;65(1-2):54-57. doi: 10.1159/000508556. Epub 2020 Jul 2.
Antiangiogenic chemotherapy is a common treatment option for patients with advanced ovarian cancer (OC) and has been proven to be effective and generally safe. Nevertheless, in rare cases, these drugs can give serious complications such as gastrointestinal perforations that can be even mortal or very difficult to treat and can heavily impact the clinical management. We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.
抗血管生成化疗是晚期卵巢癌（OC）患者的常见治疗选择，已被证明有效且通常安全。然而，在极少数情况下，这些药物会引起严重的并发症，如胃肠道穿孔，甚至可能致命或非常难以治疗，并会严重影响临床管理。我们报告了一例在辅助治疗中使用贝伐珠单抗联合化疗的晚期 OC 患者发生贝伐珠单抗诱导的胃穿孔的罕见病例。由于患者的临床状况脆弱，手术治疗不可行，胃穿孔成功地通过内镜缝合治疗。
